Guest Editors
Assist. Prof. Jonas Cicenas
Email: j.cicenas@mapkinases.eu
Affiliation: 1. Kaunas University of Applied Sciences , Kaunas, LT-50468, Lithuania
2. UAB CDKjc, Kaunas, LT-51338, Lithuania
3. SMK College of Applied Sciences, Klaipeda, Lithuania
Homepage:
Research Interests: kinases, cancer, kinase inhibitors as targeted therapy
Summary
Most cancers harbor a wide spectrum of gene alterations, including amplifications, deletions, translocations, inversions, frameshifts, and point substitutions. Disruptions in several key genes are nearly universal, occurring in approximately 75%–93% of patients, while mutations in other genes are less frequent but still contribute significantly to tumor initiation and progression. These genetic changes may arise from germline inheritance or occur spontaneously during a patient's lifetime. Gene mutations can either enhance protein function, sometimes rendering it constitutively active, or impair it, potentially abolishing normal activity. Such alterations disrupt critical cellular processes, including proliferation, motility, adhesion, apoptosis, autophagy, DNA repair, and genomic stability, thereby promoting tumor development, growth, and metastasis. This Special Issue aims to comprehensively explore the mechanisms, prevalence, and therapeutic implications of gene mutations across diverse solid tumors, as well as hematologic malignancies such as leukemias and lymphomas.
Keywords
cancer, mutations, therapy, genetic variant
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue